Madrigal Pharmaceuticals, Inc. MDGL
Sales up 432.1%, free cash flow up to -$190.0M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (33, from the latest 10-K and 10-Q)
- EPS (ttm)
- -8.05
- Sales (ttm)
- 1.4B
- Net income (ttm)
- -155.5M
- Sales growth
- +432%
- EPS growth
- -
- Sales Q/Q
- +50.1%
- Free cash flow
- -168.7M
- Gross margin
- -
- Oper. margin
- -10.7%
- Net margin
- -10.9%
- FCF margin
- -11.8%
- ROE
- -24.8%
- ROA
- -10.8%
- R&D / sales
- 40.5%
- Dividend
- -
- Debt/Eq
- 0.54
- Curr. ratio
- 3.05
- Cash
- 514.6M
- Op. cash flow (ttm)
- -157.0M
- EBITDA
- -298.6M
- EBITDA margin
- -31.2%
- Net debt
- -173.4M
- Quick ratio
- 2.89
- Interest cover
- -13.45
- FCF after stock pay
- -288.1M
- Stock pay / sales
- 10.2%
- Shares out.
- 23.2M
- Shares Y/Y
- +5.5%
- Book / share
- 26.99
- Cash / share
- 22.15
- Sales / share
- 61.47
- Asset turnover
- 1.00
- Days sales out.
- 51
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2017 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
MDGL against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. | $1.4B | +432% | - | -10.9% | -24.8% | -11.8% | 0.54 |
| INSM INSMED Inc | $1.5B | +66.7% | 84.4% | -39.9% | -83.4% | -41.3% | 0.75 |
| LIVN LivaNova PLC | $1.5B | +10.7% | 67.8% | 13.0% | 14.3% | 8.6% | 0.22 |
| ADUS Addus HomeCare Corp | $1.5B | +23.2% | 32.3% | 7.4% | 9.4% | 9.6% | 0.02 |
| HAE Haemonetics Corp | $1.4B | -2.0% | 59.6% | 7.5% | 11.6% | 21.6% | 1.27 |
| PGNY Progyny, Inc. | $1.3B | +10.4% | 24.9% | 6.8% | 22.0% | 13.4% | - |
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2024 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin below the peer median-10.9% vs 6.8%
-
Return on equity below 15%-24.8%
-
A profit in 0 of 9 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -13.5× interest expense
-
Debt smaller than equityDebt / equity 0.54 on the latest balance sheet (peer median 0.69)
-
Current assets cover current liabilitiesCurrent ratio 3.05
-
More cash than debtNet cash $958.2M
Cash and shareholders
-
Free cash flow positive in 0 of 9 years−$190.0M last year
-
Share count up over 5 years+45.2%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
$461.0M of principal due, schedule of Sep 30, 2026
Debt
From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
MDGL's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180.1M | 958.4M |
| Cost of revenue | - | - | - | - | - | - | 0 | 0 | 6.2M | - |
| R&D | 15.9M | 24.4M | 25.4M | 72.3M | 184.8M | 205.2M | 245.4M | 272.4M | 236.7M | 388.5M |
| SG&A | 9.3M | 7.7M | 15.3M | 22.6M | 21.9M | 37.3M | 48.1M | 108.1M | 435.1M | 813.8M |
| Operating income | -25.2M | -32.1M | -40.7M | -95.0M | -206.7M | -242.5M | -293.6M | -380.5M | -497.9M | -300.1M |
| Interest expense | 1.2M | - | - | - | 0 | 0 | 4.0M | 12.7M | 14.7M | 22.3M |
| Pretax income | - | - | - | - | - | - | - | -373.6M | -465.9M | -158.5M |
| Income tax | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -26.4M | -31.2M | -32.8M | -83.9M | -202.2M | -241.8M | -295.4M | -373.6M | -465.9M | -288.3M |
| EPS (diluted) | -5.07 | -2.54 | -2.22 | -5.45 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 | -12.85 |
| Diluted shares | - | - | - | - | 15.4M | 16.5M | 17.1M | 18.7M | 21.3M | 22.4M |
| Depreciation & amortization | 156 | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 1.1M | 1.5M |
| EBITDA | -25.2M | -32.0M | -40.6M | -94.9M | -206.2M | -242.1M | -293.1M | -380.0M | -496.8M | -298.6M |
| Operating margin | - | - | - | - | - | - | - | - | -276.4% | -31.3% |
| Net margin | - | - | - | - | - | - | - | - | -258.6% | -30.1% |
| Revenue growth | - | - | - | - | - | - | - | - | - | +432% |
Balance sheet
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 19.1M | 148.6M | 57.4M | 46.7M | 54.0M | 36.3M | 331.5M | 99.9M | 100.0M | 198.7M |
| Short-term investments | - | 42.9M | 426.3M | 392.3M | 230.1M | 234.1M | 27.2M | 534.2M | 826.2M | 784.9M |
| Receivables | - | - | - | - | - | - | - | 0 | 53.8M | 134.5M |
| Inventory | - | - | - | - | - | - | - | 0 | 34.1M | 74.8M |
| Current assets | 41.2M | 192.0M | 485.2M | 440.2M | 285.2M | 271.7M | 361.4M | 637.3M | 1.0B | 1.2B |
| Property & equipment | 3K | 301K | 227K | 1.2M | 1.0M | 851K | 601K | 1.6M | 2.2M | 1.5M |
| Other intangible assets | - | - | - | - | - | - | - | 0 | 4.7M | 7.4M |
| Total assets | 41.2M | 192.3M | 485.4M | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 1.0B | 1.3B |
| Accounts payable | 762K | 1.9M | 2.5M | 1.2M | 1.0M | 21.4M | 23.8M | 28.0M | 43.6M | 48.9M |
| Current liabilities | 4.8M | 10.1M | 8.4M | 25.1M | 46.6M | 76.8M | 115.9M | 118.5M | 169.3M | 310.3M |
| Total debt | - | - | - | - | - | 0 | 69.7M | 115.5M | 117.6M | 339.9M |
| Total liabilities | 4.8M | 10.1M | 8.4M | 25.5M | 47.0M | 77.2M | 165.2M | 235.2M | 287.9M | 656.9M |
| Shareholders' equity | 36.4M | 182.3M | 477.0M | 416.6M | 240.0M | 196.1M | 197.4M | 405.3M | 754.4M | 602.7M |
| Retained earnings | -75.3M | -106.5M | -139.3M | -223.2M | -425.5M | -667.3M | -962.7M | -1.3B | -1.8B | -2.1B |
Cash flow
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -17.6M | -22.3M | -25.5M | -41.6M | -157.6M | -183.9M | -224.9M | -324.2M | -455.6M | -189.6M |
| Capital spending | 3K | 125K | 22K | 172K | 334K | 209K | 217K | 1.5M | 1.5M | 467K |
| Free cash flow | -17.6M | -22.4M | -25.5M | -41.8M | -157.9M | -184.1M | -225.1M | -325.7M | -457.0M | -190.0M |
| Stock-based pay (added back) | 7.9M | 3.3M | 13.5M | 22.8M | 20.7M | 26.9M | 31.6M | 49.7M | 79.9M | 98.1M |
| Free cash flow after stock pay | -25.5M | -25.7M | -39.0M | -64.6M | -178.6M | -211.0M | -256.7M | -375.4M | -536.9M | -288.1M |
| Investing cash flow | 22.0M | -22.0M | -380.1M | 30.7M | 159.8M | -5.1M | 206.7M | -502.5M | -274.4M | 32.3M |
| Financing cash flow | 14.5M | 173.8M | 314.3M | 235K | 5.1M | 171.2M | 313.5M | 595.1M | 735.1M | 256.0M |
Stock-based pay and leases
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 7.9M | 3.3M | 13.5M | 22.8M | 20.7M | 26.9M | 31.6M | 49.7M | 79.9M | 98.1M |
| Stock-based pay / revenue | - | - | - | - | - | - | - | - | 44.3% | 10.2% |
| Operating lease cost | - | - | - | 386K | 300K | 400K | 800K | 1.1M | 900K | 1.9M |
| Operating lease cash paid | - | - | - | - | - | - | 700K | 1.1M | 1.1M | 1.4M |
| Right-of-use assets | - | - | - | 675K | 785K | 797K | 602K | 1.7M | 2.4M | 4.9M |
| Operating lease liabilities | - | - | - | 676K | 786K | 797K | 602K | 1.7M | 2.0M | 7.7M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.